Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 8—August 2004
Research

Antimicrobial Drug Use and Methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000

Dominique L. Monnet*, Fiona M. MacKenzie†Comments to Author , José María López-Lozano‡, Arielle Beyaert§, Máximo Camacho§, Rachel Wilson†, David Stuart†, and Ian M. Gould†
Author affiliations: *Statens Serum Institut, Copenhagen, Denmark; †Aberdeen Royal Infirmary, Aberdeen, Scotland; ‡Hospital Vega Baja, Orihuela (Alicante), Spain; §University of Murcia, Murcia, Spain

Main Article

Figure 3

Evolution of the monthly % methicillin-resistant Staphylococcus aureus (MRSA) and monthly sum of lagged antimicrobial use as identified in polynomial distributed lag (PDL) model: macrolides (lags of 1 to 3 months), third-generation cephalosporins (lags of 4 to 7 months), and fluoroquinolones (lags of 4 and 5 months), Aberdeen Royal Infirmary, January 1996–December 2000.

Figure 3. Evolution of the monthly % methicillin-resistant Staphylococcus aureus (MRSA) and monthly sum of lagged antimicrobial use as identified in polynomial distributed lag (PDL) model: macrolides (lags of 1 to 3 months), third-generation cephalosporins (lags of 4 to 7 months), and fluoroquinolones (lags of 4 and 5 months), Aberdeen Royal Infirmary, January 1996–December 2000.

Main Article

Page created: March 01, 2011
Page updated: March 01, 2011
Page reviewed: March 01, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external